Showing results (241-250 of 410) with videos related to
Sort By:
Pageof 41
American Journal of Otolaryngology|April 11, 2024
Metastatic merkel cell carcinoma to the thyroid gland: Case report and review of the literatureSalmaan Sayeed, Danielle Kapustin, Samuel J Rubin, et al.Journal of Translational Medicine|June 6, 2022
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to malesMariam Saad, Sandra J Lee, Aik Choon Tan, et al.Cell Reports. Medicine|October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironmentJames R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.Journal for Immunotherapy of Cancer|January 25, 2022
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primaryAhmad A Tarhini, Sandra J Lee, Aik-Choon Tan, et al.Cancer|April 26, 2017
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 studyEytan Ben-Ami, Constance M Barysauskas, Sarah Solomon, et al.Cancer Immunology Research|June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockadeZachary A Cooper, Vikram R Juneja, Peter T Sage, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunityGerald P Linette, Dongsheng Zhang, F Stephen Hodi, et al.Proceedings of the National Academy of Sciences of the United States of America|April 17, 2003
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi, Martin C Mihm, Robert J Soiffer, et al.The Lancet. Oncology|June 9, 2016
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trialJeffrey S Weber, Geoff Gibney, Ryan J Sullivan, et al.Science Translational Medicine|July 20, 2018
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanomaScott J Rodig, Daniel Gusenleitner, Donald G Jackson, et al.Pageof 41